

# WELCOME YE TO TAMPA



# Goals for the EAC meeting

- **Respond to questions raised at 2018 visit**

- Total Cancer Care and ORIEN
- Data Science

- **Summarize progress since 2018 visit**

- Community Outreach & Engagement
- Cancer Research Career Development & Education
- Revisions to two Shared Resources

- **Introduce new leadership**

- ACDs, Program Leaders, Shared Facility Leaders
- Give them experience

- **Get feedback on revised Program Aims**

# Today's Agenda

## Morning

State of the Center	8:00 – 9:00
Community Outreach & Engagement	9:00 – 9:25
Cancer Research Career Development & Education	9:25 – 9:50
Break	9:50 – 10:05
Population Science	10:05 – 10:35
Data Science	10:35 – 10:55
Shared Resources	
▪ Biostatistics & Bioinformatics	10:55 – 11:15
▪ PRISM Core	11:15 – 11:35
Clinical Science	11:35 – 11:55

## Afternoon

Lunch	11:55 – 12:35
Programs:	
▪ Chemical Biology & Molecular Medicine	12:35 – 12:55
▪ Immunology	12:55 – 1:15
▪ Cancer Biology & Evolution	1:15 – 1:35
▪ Cancer Epidemiology	1:35 – 1:55
▪ Health Outcomes & Behavior	1:55 – 2:15
Executive Session	2:15 – 2:35
Report Out	2:35 – 2:45
Meeting Adjourns	2:45

# State of the Center

---

Tom Sellers, PhD, MPH  
Center Director



TO CONTRIBUTE TO THE PREVENTION AND CURE OF CANCER



# Agenda

---

● Leadership & Recruitment Updates

● Accolades & Highlights

● Strategic Plans

● Progress

● Summary

# Associate Center Director, Community Outreach & Engagement

- Recruited to Moffitt in 2003 from NCI
- A record of service and leadership:
  - Vice-Chair, Health Outcomes & Behavior Department
  - Led the Survey Methods Core Taskforce
- Co-Director of the community-based Breast Cancer Genetics Research Education & Advocacy Team (B-GREAT)
- Exceptional scholarship:
  - PI or Co-PI of three R25s
  - Moffitt-Ponce U54 Co-Leader of the Outreach Core, Co-Investigator of Research Project 1, & Co-Leader of Research Education
  - Nearly 200 peer-reviewed publications

**Susan Vadaparampil, PhD**



# Director, Cancer Research Career Development & Education



**Ken Wright, PhD**

- Recruited to Moffitt in 1997 from UNC
- A record of service and leadership
  - Interim Co-Leader of Immunology (2013-16)
  - Vice Chair, Immunology Department
- Founding Director, Cancer Biology PhD Program (est. 2002)
- Founding member of the national Cancer Biology Training Consortium (est. 2005)
  - Served on its Executive Board for 3 years
- Funding
  - U54 Ponce Health Sciences/Moffitt Partnership (PI)
  - R01 on Natural Killer Cell Regulation by PRDM1 & IRF4/8 (PI)
  - R01 targeting SIRT1 in Mantel Cell Lymphoma (Co-PI)
- Over 75 publications

# Leadership Structure








## Research Executive Committee



### Sellers

EVP/Center Director

## Associate Center Directors

Cleveland	Sullivan	Rollison	Tworoger	Mulé	Springer	Vadaparampil
 Basic Science	 Clinical Science	 Data Science	 Pop. Science	 Transl. Science	 Admin.	 Comm. Outreach Engage.

## Scientific Leadership Committee

Senior Leadership	Centers & Institutes	Programs	Research Departments	Cancer Research Career Development & Education
Center Director 6 ACDs	4 CoE Directors 2 DFPMI Directors	6-10 Program Leaders	3 Chairs	 1 Director <b>Wright</b>

# Transitions



Said Sebti, PhD

- Stepped down from CBMM Co-Leader role
- Continues to have an active lab, including PI of an R35



Eric Haura, MD

- Transitioning out of CBMM Program Co-Leader role
- Remains Director, Lung Cancer Center of Excellence
- Recently appointed Interim Chair, Thoracic Oncology



Scott Antonia MD, PhD

- Departing to Duke to lead center for personalized health care
- Served as Program Co-Leader of Immunology for 14 years

# Program Co-Leader, Chemical Biology & Molecular Medicine



Jhanelle Gray, MD

- Recruited to Moffitt in 2007 after residency
- Since 2013, Director for Clinical Research in Thoracic Oncology Department
- Peer-Review Funded (DOD & FL Biomedical)
- Served as PI of over 50 clinical trials (19 IITs)
- Over 70 publications



## Program Co-Leader, Immunology



Fred Locke, MD

- Recruited in 2010 from U of Chicago, Illinois
- Vice Chair of BMT & Cellular Immunotherapy Department
- Chair, Immunotherapy Working Group
- Chair, Cellular Therapy Advisory Committee
- PI of a K23 and former NCI CCITLA Awardee
- Co-led ZUMA-1 Trial, which led to the first FDA approved CAR T therapy for adults

# New Scientific Directors Appointed



- **Brooke Fridley, PhD**

- Leads a newly combined **Biostatistics & Bioinformatics Shared Resource (BBSR)**
- Chair of Biostatistics & Bioinformatics Department



- **Brian Gonzalez, PhD**

- Leads newly named and expanded **Participant Research, Interventions, & Measurement (PRISM) Core Facility** (formerly Survey Methods)
- Assistant Member, Health Outcomes & Behavior Program

# New Scientific Directors: Tissue Core



- **Conor Lynch, PhD**

- Co-Scientific Director of the Tissue Core
- Member, Cancer Biology & Evolution Program
- Associate Member, Tumor Biology Department



- **Ken Tsai, MD, PhD**

- Co-Scientific Director of the Tissue Core
- Melanoma & Skin Center of Excellence Co-Director
- Member, Chemical Biology & Molecular Medicine Program
- Sr. Member, Pathology Department

# Leader, Phase 1 Program

---



- New Position
- Adds to her role as Medical Director of the Clinical Research Unit
- Position addresses concerns of Dr. Sullivan's commitments

# New EVP/Chief Philanthropy Officer

## Maria Muller




- 20+ years of experience in fundraising
- Recruited from Boston
  - Was deputy director of the Museum of Fine Arts
  - Consulted with the Harvard Art Museums
- Has led multiple \$100 million or more campaigns
- Will advance and execute the strategic vision of philanthropy
- Will support research priorities


# Key Senior Members



- From Mayo Clinic
- Director, DeBartolo Family Personalized Medicine Institute
- Senior Member & Vice Chair, GU Oncology




- From Cleveland Clinic
- Senior Member & Program Leader, Neuro-Oncology
- Chief of Neurosurgery



- From Mayo Clinic
- Artificial Intelligence Officer
- Senior Member
- Biostatistics & Bioinformatics



# 25 New Members



# Agenda

---

 Leadership & Recruitment Updates

 Accolades & Highlights

 Strategic Plans

 Progress

 Summary

# National Recognition

**BEST  
HOSPITALS**

**U.S. News** & WORLD REPORT

**NATIONAL  
CANCER  
2018-19**

- Top Cancer Hospital in the Southeast
- Best in Florida





# National & Local Recognition



**10 Years**

In a row Moffitt Awarded  
CEO Cancer Gold Standard

**Best** Place to Work

# Diverse & Inclusive



**100%**

Moffitt Leaders Completing Diversity & Inclusion Training

**44%**

Of Executive Positions are Filled by Women & Minorities

# Dr. Mulé Appointed to CCSG Parent Committee



**Jim Mulé, IPhD**

- Appointed Subcommittee A Cancer Centers of the NCI Initial Review Group
- 3<sup>rd</sup> time appointed to Committee
- Term will be from July 1, 2018 to June 30, 2022



# Anna Giuliano, PhD

## Awarded ACS Clinical Research Professor




Awarded to those  
who have made  
**seminal contributions**  
in an area of cancer control  
that have changed the  
direction of research

- \$400,000 total costs (5 years)
- The most prestigious research grant made by the American Cancer Society
- Title can be used throughout the rest of her career




# 1<sup>st</sup> FDA Approved CAR T



- Fred Locke, MD Co-led phase I CAR-T Study (ZUMA-1)
- Published in the *New England Journal of Medicine* and *Molecular Therapy* last year.
- Led to the first FDA approved CAR T therapy

Breakthrough led to national exposure including interviews in *Time*, the *New York Times*, *Washington Post*, and *Newsweek*.



## CAR T

CAR T is a personalized therapy using the patient's own immune cells, or T cells, to fight cancer. For this treatment, a patient's T cells are removed from their blood and sent to a lab where the cells are genetically modified to better enable them to identify and attack cancer cells. Scientists add a chimeric antigen receptor, or CAR, to each T cell. These CARs act like a GPS that directs the T-cells to target and attack cancer. When the CAR T cells are infused back into the patient's blood, the immune cells seek and destroy the cancer.

### TIME

#### The FDA Just Approved a New Way of Fighting Cancer Using Personalized Gene Therapy

"We think this therapy is here to stay. It's very different from chemo," says Dr. Frederick Locke, research director and clinical director of immune cell therapy at Moffitt Cancer Center in Tampa. "This is a living, breathing therapy that we are putting back into the patient that can persist, and continue to fight against the cancer. It's pretty amazing."

### The New York Times

#### FDA Approves second gene-altering treatment for cancer

"The results are pretty remarkable," said Dr. Frederick L. Locke, a specialist in blood cancers at the Moffitt Cancer Center in Tampa, and a leader of a study of the new treatment. "We're excited. We think there are many patients who may need this therapy." He added, "These patients don't have other options."

### The Washington Post

#### Cutting-edge immunotherapy treatment approved for another deadly cancer

Kite's "vein-to-vein" turnaround period — from cell extraction to reinfusion — is about 17 days, according to Frederick Locke, an oncologist at Moffitt Cancer Center in Tampa and co-leader of the Kite trial.

### AP Associated Press

#### US Regulators Approve 2nd Gene Therapy For Blood Cancer

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta. Also posted to the Florida Times Union, WSBTV, News9, WOKV, TDS, TruVista, Windstream, PeoplePC, Midco,

### Newsweek

#### Gene Therapy: Latest CAR T Therapy for Cancer Signals New Era of Life-Saving Treatments

One of those hospitals will be Moffitt Cancer Center in Tampa, Florida. "We're really excited. We treated a lot of patients on that trial, and we think that it will be a therapy that is here to stay," Dr. Frederick Locke told Newsweek. Locke was one of the principal investigators of the key clinical trial at Moffitt and has been a scientific adviser to Kite, the company that first developed Yescarta.



f @MOFFITTGR  
@MOFFITTCANCERCENTERPUBLICPOLICY

# FDA approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy



JOURNAL OF CLINICAL ONCOLOGY

RAPID COMMUNICATION

## Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial

*Jonathan Strosberg, Edward Wolin, Beth Chasen, Matthew Kulke, David Bushnell, Martyn Caplin, Richard P. Baum, Pamela Kunz, Timothy Hobday, Andrew Hendifar, Kjell Oberg, Maribel Lopera Sierra, Thomas Thevenet, Ines Margalet, Philippe Ruszniewski, and Eric Krenning, on behalf of the NETTER-1 Study Group*

Newly-Approved therapy provides improved Quality of Life for patients with advanced metastatic midgut neuroendocrine tumors

# Grant Highlight



- Awarded Rita Allen Foundation Grant
- First Moffitt recipient of this award
  - Elsa Flores had one when at MD Anderson
- Award: \$500,000 total costs over 5 years
- Project will develop synthetic proteins that reprogram the ubiquitination system to eradicate disease-associated receptors from the cell membrane



# Grant Highlight

José Conejo-Garcia, PhD

- Awarded NCI U01 entitled “B cell-dependent anti-tumor immunity in ovarian cancer”
- \$3,907,925 in total costs over 5 years

“Our work will exert a profound effect in the field by elucidating how epigenetic programs controlled by SATB1 govern the generation of TFH cells at tumor beds in a TGF- $\beta$ -dependent manner. Recapitulating these mechanisms in vivo will pave the way for more effective immunotherapies aimed to promote combined humoral and T cell responses through the orchestration of TLS in unresectable/metastatic tumors, and could lead to the identification of antibodies with anti-tumor activity spontaneously produced at tumor beds.”



# Agenda

---

 Leadership & Recruitment Updates

 Accolades & Highlights

 Strategic Plans

 Progress

 Summary



# Institutional Strategic Plan

## **IMPACT 2028**

Expanding Moffitt's leadership in the oncology market and developing a personalized care model driven by preeminent research and digital capabilities that enhances value and patient experience

# Institutional Strategic Plan: 3 Pillars

## Research Foci

### Personalized Care Continuum



Management of the Patient's  
Care Throughout the Journey

- All 5 CCSG Programs
- All 4 CoEs

### Digital Care & Discovery Accelerator



Delivering Breakthroughs  
with New Digital & Data  
Capabilities

- Health & Research Informatics
- Patient Reported Information & Outcomes
- mHealth

### Market Expansion



Rapid Expansion Through  
Satellites & Partnerships to  
Reach More People

- Clinical trials
- Primary prevention
- Health Care Delivery
- Community Outreach

# Detailed Research Strategic Plan Roadmap

[illegible]

# Research Strategic Plan Summary

## Fundamental Principles

**Retain NCI Comprehensive Cancer Center Status**

**Drive exceptional science and innovation**

**Must support IMPACT 2028**

**First in human trials that change clinical practice**

## Desired Future State

**Moffitt is THE best place on earth for science, recruiting and retaining the best talent, out-competing for grant funding, and achieving international recognition for the impact it has on changing paradigms, clinical and public health practice, and policy.**

## Strategies

### Optimizing Intellectual Capability

- Recruit/develop talent
- Explore new mentoring strategies
- Enhance recruiting materials/tactics
- Broaden multi-institutional collaborations

### Creating Fuel for Discovery

- Diversify funding sources
- Build on & monetize unique capabilities
- Enhance infrastructural support functions
- Enhance Foundation focus

### Generating Impact

- Thought leadership & (inter)national exposure
- Develop strategies for data
- Foster science impacting catchment
- Expand unique capabilities

# Agenda


---

- Leadership & Recruitment Updates
- Accolades & Awards
- Scientific Highlights
- Strategic Plans
- **Progress**
- Summary




# CCSG Profile



## Membership



## Grants (Annual Direct Costs)



## Publications



# Program Health

## NCI Funding Recommendations:

5 Independent PIs

7 R01s or Equivalent Projects

	Total Members	Peer Review Funded PIs	R01/Equivalent Projects (# PIs)	R01/Equivalent Annual Direct Costs
✓ Cancer Biology & Evolution	28	18	16 (9)	\$6.6 M
✓ Cancer Epidemiology	26	19	14 (10)	\$4.8 M
✓ Chemical Biology & Molecular Medicine	55	26	24 (13)	\$6.4 M
✓ Health Outcomes & Behavior	19	9	11 (7)	\$3.1 M
✓ Immunology	38	23	17 (12)	\$6.8 M

# All Intervention Trial Accrual by Program (CY 2018)

	Treatment	Supportive Care	Prevention	Total
<b>CBMM</b>	946	6	23	975
<b>IMM</b>	206	0	16	222
<b>CBE</b>	9	0	0	9
<b>HOB</b>	4	81	52	137
<b>CE</b>	26	0	439	465
<b>Total</b>	1191	87	530	1808

# Industry Alliances Update

## GLOBAL FUNDING

FY18	2014 – 2018
<b>\$61M</b>	<b>\$111M</b>

## MAJOR INDUSTRY ALLIANCES

Bristol-Myers Squibb	Incyte
Celgene	Iovance

## STARTUPS

- CvergenX, Inc.
- GLG Pharma, LLC
- Interpares Biomedicine, Inc.
- Maya Sciences, LLC
- Modulation Therapeutics, Inc.
- Tampa Medical Innovations, Inc.
- TechnoGenesys, Inc.
- Venous Tourniquets, Inc.

## PATENTING & CONTRACTING

### INTELLECTUAL PROPERTY DISCLOSURES

FY18	2003-2018
<b>36</b>	<b>555</b>

### U.S. PATENTS ISSUED

FY18	2003-2018
<b>26</b>	<b>112</b>

### EXECUTED AGREEMENTS

FY18	2003-2018
<b>677</b>	<b>5442</b>

### LICENSE AGREEMENTS

FY18	2003-2018
<b>14</b>	<b>190</b>

# Industry Alliances Research Impact

REVENUE RECOGNIZED	
FISCAL YR	PROJECTS
FY15	\$10.84
FY16	\$4.5M
FY17	\$7.39M
FY18	\$25.09M
FY19	\$7.04M
FISCAL YR	OTHER REVENUE
FY15-FY18	\$18.34M

FTEs SUPPORTED
ON 12/31/17
<b>28.9</b> 89 EMPLOYEES 34 ACTIVITIES
ON 06/30/18
<b>38.7</b> 100 EMPLOYEES 39 ACTIVITIES

GRANTS & PUBLICATIONS 2016-2018	
GRANTS SUBMITTED*	MANUSCRIPTS SUBMITTED
25	14
GRANTS AWARDED	MANUSCRIPTS PUBLISHED*
8 \$5.54M	10 AVG IF = 7.65
*Includes pending & denied	*Includes in press



# Industry Alliance Highlight: Marco Davila, MD, PhD

- Agreement with **Atara Biotherapeutics**
- A collaboration to develop multi-targeted CAR T immunotherapies designed to address cancers with diverse cell types that often become resistant to treatment such as AML and B-cell malignancies
- 4 significantly funded research projects, each for 3 years
- Largest independent license agreement to date for Moffitt




“I look forward to rapidly advancing our CAR T engineering and multi-antigen targeting technologies with Atara to address the high unmet need in patients with advanced AML and B-cell malignancies.”

# Leading to Peer-reviewed Funding (2018)



Lixin Wan, PhD

- Melanoma Research Alliance
- \$225,000 for 3 years



Jose Conejo-Garcia,  
MD, PhD

- NCI R01 Renewal
- \$1,838,250 for 5 years



Keiran Smalley, PhD

- Florida Biomedical
- \$815,283 for 3 years




Brian Ruffell, PhD

- Florida Biomedical
- \$815,289 for 3 years



# Leading to Publication



## Clinical Cancer Research

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma

Douglas B. Johnson, Jennifer Bordeaux, Ju Young Kim, Christine Vaupel, David L. Rimm, Thai H. Ho, Richard W. Joseph, Adil I. Daud, Robert M. Conry, Elizabeth M. Gaughan, Leonel F. Hernandez-Aya, Anastasios Dimou, Pauline Funchain, James Smithy, John S. Witte, Svetlana B. McKee, Jennifer Ko, John M. Wrangle, Bashar Dabbas, Shabnam Tangri, Jelveh Lameh, Jeffrey Hall, Joseph Markowitz, Justin M. Balko, and Naveen Dakappagari



## Cancer Cell

TIM-3 Regulates CD103<sup>+</sup> Dendritic Cell Function and Response to Chemotherapy in Breast Cancer

Álvaro de Mingo Pulido,<sup>1</sup> Alycia Gardner,<sup>1,2</sup> Shandi Hiebler,<sup>1</sup> Hatem Soliman,<sup>1,3</sup> Hope S. Rugo,<sup>4</sup> Matthew F. Krummel,<sup>5</sup> Lisa M. Coussens,<sup>6</sup> and Brian Ruffell<sup>1,3,7,\*</sup>





# Centers of Excellence



Keiran Smalley, PhD

MELANOMA &  
SKIN CANCER

Eric Haura, MD

LUNG  
CANCER

Anna Giuliano, PhD

IMMUNIZATION &  
INFECTION RESEARCH

Alexander Anderson, PhD

EVOLUTIONARY  
THERAPY

## Updates:

- Directors received named Scholars based on Foundation funds
- Over \$2.5M in philanthropic funds raised in FY2018 and over \$5M raised so far in FY2019
- CIIRC
  - Renamed “Center of Excellence in IMMUNIZATION and Infection Research” to reflect expanded focus
  - Shari Pilon-Thomas, PhD, Associate Member, Immunology Program, appointed Co-Director

# Building for Tomorrow: Clinic Support Services

- Opens Spring 2020
- 8 story; 200,000 sf
  - Behind Hospital on Magnolia Campus
- To house:
  - Office functions
  - Executive suites
  - Clinical & anatomic pathology labs
  - 5<sup>th</sup> floor for dry lab research





# Building for Tomorrow

## **Magnolia Campus Renovation**

- New inpatient expansion (10/19)
  - 12 new inpatient beds
  - 8 treatment/observation bays
- Expansion of various services
  - Multiple projects 2020-2023

## **New Solid Tumor Hospital**

McKinley East Campus (Spring 2023)

- 400,000 sf
- Phase 1: 128 beds & 24 OR suites
- Phase 2: 76 beds

## **5 new outpatient clinic sites**

- Over the next 5 years
- New construction or partnerships
- 25-30K sf per site
- Medical oncology, infusion, & radiation oncology

## **New research tower**

- Estimated 150-200K sf
- Research Master Plan
- Requires state and philanthropic funding



# Agenda

---

 Leadership & Recruitment Updates

 Accolades & Highlights

 Strategic Plans

 Progress

 Summary

# Questions (for the end of the day)

---

- Do you support the revised Program Aims?
- Are we making adequate progress?
- Are there blind spots we appear to have missed?

# Debbie Magley

## *In Memoriam*

- Battled ovarian cancer for over two years, passing away in September 2018 at the age of 62
- Just shy of 20 years of service at Moffitt
- Was essential to CCSG support & our success
  - 3 CCSG renewals
  - EAC annual meeting support since 2003



# Associate Center Director, Community Outreach & Engagement

- Recruited to Moffitt in 2003 from NCI
- A record of service and leadership:
  - Vice-Chair, Health Outcomes & Behavior Department
  - Led the Survey Methods Core Taskforce
- Co-Director of the community-based Breast Cancer Genetics Research Education & Advocacy Team (B-GREAT)
- Exceptional scholarship:
  - PI or Co-PI of three R25s
  - Moffitt-Ponce U54 Co-Leader of the Outreach Core, Co-Investigator of Research Project 1, & Co-Leader of Research Education
  - Nearly 200 peer-reviewed publications

**Susan Vadaparampil, PhD**





# Community Outreach, Engagement, (& Equity)

---

Susan T. Vadaparampil, PhD, MPH

Associate Center Director for Community Outreach, Engagement, & Equity



TO CONTRIBUTE TO THE PREVENTION AND CURE OF CANCER

# Agenda

---


- Moffitt COE&E Vision & Aims
- COE&E Activities, Structure, Integration
- Short-term Plans & Strategies
- Questions & Feedback

# Agenda

---

- Moffitt COE&E Vision & Aims
- COE&E Activities, Structure, Integration
- Short-term Plans & Strategies
- Questions & Feedback


# COE&E Vision



To maximize the impact of Moffitt's research through engagement and equity in our Cancer Center catchment area and beyond.

# Engagement:

Foundational to the Translational Continuum





# COE&E Aims

- 1 Identify and prioritize catchment area needs across the cancer continuum
- 2 Address catchment area needs by fostering innovative research, outreach and education across the cancer continuum
- 3 Accelerate the adoption of evidence based practices and policies at the local, state, and national level to address catchment area needs
- 4 Monitor impact of COE&E efforts in the catchment area and beyond

# Agenda

---

- Moffitt COE&E Vision & Aims
- COE&E Activities, Structure, Integration
- Short-term Plans & Strategies
- Questions & Feedback

# MCC Broad-Based Community Partnerships



## Tampa Bay Community Cancer Network

- Est. in 2005
- Focus: Medically underserved populations in MCC Catchment Area
- 26 community partners

# MCC Topic Specific Community Partnerships



## **Breast Cancer Research Genetics and Advocacy Team (B-GREAT)**

- Est. 2005
- Focus: Breast cancer disparities in Blacks
- 8-10 members

# MCC Institutional Activities Supporting COE&E

## Diversity Office



M-POWER



Community Benefit



Diversity Training & Language Services

## Clinical Outreach Activities



Patient & Family Advisory Council



Mole Patrol

The Lung and Thoracic Tumor Education (LATTE) Spring Forum

Lung Cancer Education



AYA Meet Up

## Payer Strategies Strategic Partnerships Government Relations



Employer Outreach




Clinical Partnerships




Moffitt Tallahassee Day



# COE Integration



# Office of COE&E Structure




# Agenda

---

- Moffitt COE&E Vision & Aims
- COE&E Activities, Structure, Integration
- Short-term Plans & Strategies
- Questions & Feedback

# Many Stakeholders—Similar Approach: Begin by Creating Shared Priorities



# Stimulating COE&E Research

## Build to Strengths

- Leverage strong faculty and community interest
- Match strengths to priorities
- Utilize existing internal funding mechanisms

## Foster Additional Research

- Inform and inspire researchers and community stakeholders about catchment area research
- New initiatives: Catchment area supplements
- Provide data

## Support for Grant Applications

- Assistance finding community research partners
- Template language for grants with COE&E components
- Assistance writing lay summaries/abstracts



# Enhancing COE&E Outreach and Engagement

## Build to Strengths

- Leverage strong faculty and community interest
- Match strengths to priorities
- Utilize existing outreach and engagement activities

## Focus on Impact

- Identify gaps
- Harmonize metrics of impact
- Create partnerships to expand reach
- Partner with advocacy and policy minded groups

## Enhance Mutual Benefit

- Assistance meeting community cancer needs
- Partnerships for community grants/activities
- Sharing of information and resources

# Next Steps



# Agenda

---

- Moffitt COE&E Vision & Aims
- COE&E Activities, Structure, Integration
- Short-term Plans & Strategies
- Questions & Feedback

# Questions

---

- Does our vision and aims capture the spirit of COE&E?
  - Thoughts on adding '&E'?
- Is the structure of COE&E sufficient given the many other institutional activities taking place that address COE&E?
- How do we highlight activities that address both COE&E and Education?

# Director, Cancer Research Career Development & Education



**Ken Wright, PhD**

- Recruited to Moffitt in 1997 from UNC
- A record of service and leadership
  - Interim Co-Leader of Immunology (2013-16)
  - Vice Chair, Immunology Department
- Founding Director, Cancer Biology PhD Program (est. 2002)
- Founding member of the national Cancer Biology Training Consortium (est. 2005)
  - Served on its Executive Board for 3 years
- Funding
  - U54 Ponce Health Sciences/Moffitt Partnership (PI)
  - R01 on Natural Killer Cell Regulation by PRDM1 & IRF4/8 (PI)
  - R01 targeting SIRT1 in Mantel Cell Lymphoma (Co-PI)
- Over 75 publications



# Cancer Research Career Enhancement and Related Activities (CRCERA)

---

**Kenneth Wright, PhD**

Director, Cancer Research Career Development and Education (CRCDE)

Senior Member, Immunology Program



TO CONTRIBUTE TO THE PREVENTION AND CURE OF CANCER

# Cancer Research Career Enhancement & Related Activities (CRCERA)



**Coordinate  
Integrate  
Innovate  
Report**

**on the spectrum of educational  
activities at the Cancer Center**

# CRCERA Specific Aims

---

- Build synergy across the cancer center at all career stages enhancing the scientific impact of each Program
- Facilitate each individual to maximize their cancer research and cancer care career development
- Expand diversity and health equity in the career development pipeline

# Vision

## Director of the CRCDE

- *...to become a destination site for cancer education and career development; fostering significant advancement in the detection, prevention, and cure of cancer.*

# Director of the CRCDE

---

## Mission


- *...to be the coordinating center of educational activities at Moffitt, facilitating integration, synergy, and developing innovative approaches to education, training, and career development across all sectors of the cancer center and CCSG programs.*



# Education Council


## Membership includes:

- ~20 members
- Faculty
- All PIs of education related grants
- 5 Admin. Personnel
- All trainee career levels & activities represented



# Educational Activities

- High school
- Undergraduates
- PhD and Masters students
- Post-doctoral fellows
- Junior faculty
- Staff



- Pre-med, High school
- Undergraduate Medical Ed
- Residents and Fellows
- APP, Nursing
- Allied Health, Visiting Scholars
- Clinician Scientist junior faculty

# Training and Career Development Grants



Every program is supported by funded training grants

Mechanism	Number Active (program)	Number Pending (program)
T32	1 (CE)	2 (CBE, CE)
R25	3 (HOB)	2 (All, HOB)
K	7 (CBE, CE, IMM, HOB)	5 (CBMM)
K99/R00	1 K99 (CBMM) 4 R00 (CBMM, HOB)	1 (CBMM)
F99/K00	1 F99 (CBE)	1 (IMM)
F31	1 (IMM)	2 (CBMM, IMM)
P20	1 (HOB)	0
U54	2 (All, CBE)	0
R50	1 (CBMM)	1 (IMM)
Diversity Supplements	3 (CBE, CE)	





## Cancer Biology PhD Program Majors

### New Innovation



#### Cancer Biology (CB)

- Interdisciplinary
- 60 graduates
- 27 enrolled

##### Sub-committee

- Lynch (Chair)
- Alexandrow
- Reuther

#### Cancer Immunology & Immunotherapy (CII)

- Emerging cancer therapy
- 4 enrolled

##### Sub-committee

- Pilon-Thomas (Chair)
- Beg
- Ruffell

#### Cancer Chemical Biology (CCB)

- Blended biology & chemistry
- 1 enrolled

##### Sub-committee

- Ji (Chair)
- Sebti
- Lawrence

#### Integrated Mathematical Oncology (IMO)

- Blended math & biology
- 2 enrolled

##### Sub-committee

- Enderling (Chair)
- Brown
- Altrock




# Patients/Caregivers - Researchers Forum

- Enhance understanding of the patients and caregivers cancer experience
- Promote compassion/perspective, sense of relevance/purpose
- Stimulate ideas and productivity in our researchers
- Develop communication skills with a lay and patient audience



# Key to CRCDE




# Innovation

- Mentoring across the career spectrum
- Strengthen translational training
- Expand into unique PhD Programs
- Build diversity through enhanced recruitment, retention & health equity training



# Infrastructure

- Office
- Central repository of curated grant listings, templates, and examples
- Develop real-time trainee tracking
  - data tables for training grants and progress reports
- Alumni Database
- Education Council



# Engagement






# Integration

- ☐ Cancer Biology and Evolution
- ☐ Cancer Epidemiology
- ☐ Chemical Biology and Molecular Medicine
- ☐ Health Outcomes and Behavior
- ☐ Immunology
- ☐ Centers of Excellence
- ☐ Clinical Education





# Synergy with Community Outreach, Engagement & Equity



Engage in community outreach events  
Educational workshops

# Goals for the First 6 Months

- Setup & staff the CRCDE office
- Define the metrics to be used in assessing success
- Assess numbers & activities of the current training/education groups
- Engage stakeholders in dialog to assess needs
- Set high priority goals for second 6 months



# Questions

---

- Are there perceived gaps in the training spectrum that need to be addressed?
- Are there suggestions as to the best metrics to demonstrate success?
- What are effective ways for the CRCDE and COE to interact?